Specific Biologics

Specific Biologics is a biotechnology company developing Dualase, a two-site genome-editing platform for in vivo therapeutic applications. Its editors are designed to enable predictable, efficient removal, repair, or insertion of DNA sequences while exploiting cellular repair pathways and minimizing off-target effects. The company is advancing a pipeline of therapeutics delivered using AAV or RNA-based approaches, initially targeting genetic diseases involving expanded DNA repeats, with programs spanning CNS, lung, and liver indications.